Rabacfosadine (succinate)

Rabacfosadine (GS-9219) succinate, a novel proagent of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells[1].

Product Specifications

CAS Number

[1431856-99-3]

Product Name Alternative

GS-9219 (succinate) ; VDC-1101 (succinate)

UNSPSC

12352005

Target

Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rabacfosadine-succinate.html

Solubility

10 mM in DMSO

Smiles

OC(CCC(O)=O)=O.CCOC([C@H](C)NP(COCCN1C2=NC(N)=NC(NC3CC3)=C2N=C1)(N[C@@H](C)C(OCC)=O)=O)=O

Molecular Formula

C25H41N8O10P

Molecular Weight

644.61

References & Citations

[1]Reiser H, et al. GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res. 2008 May 1;14 (9) :2824-32.|[2]De Clercq E. Tanovea® for the treatment of lymphoma in dogs. Biochem Pharmacol. 2018 Aug;154:265-269.